CINRYZE® (C1 esterase inhibitor [human]) was the first FDA-approved preventive treatment that can start at age 6, helping to reduce HAE attacks earlier in life. CINRYZE has been proven to reduce attack frequency, severity, and the use of acute treatment.1,2

Start with HAE attack prevention.

Help your patients embrace preventive treatment

Starting your patients on CINRYZE gives them access to preventive therapy along with resources and support for their journey with HAE.1

Get Patients Started

Learn about pediatric use

Find out more about the expanded indication of CINRYZE to include patients aged 6 to 11.1

Read about prevention

Dosing and Administration

CINRYZE for prevention can be self-administered or administered by a caregiver or healthcare provider.1

Learn more

OnePath® Product Support

OnePath provides patients and their caregivers with a dedicated Patient Support Manager who can assist with navigating insurance coverage, self-administration training and more.

See product support services

Request a sales representative

If you'd like to learn more about CINRYZE for your HAE patients, please get in touch.

Complete a request form


  1. CINRYZE® (C1 esterase inhibitor [human]) Prescribing Information. Shire.
  2. Zuraw BL, Busse PJ, White M, Jacobs J, Lumry W, Baker J, et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med 2010;363:6.